Early promise for Progenics' MAb HIV entry inhibitor
This article was originally published in Scrip
Executive Summary
Progenics Pharmaceuticalshas presented positive interim results from two separate Phase II trials of subcutaneous and intravenous formulations of PRO 140 – a novel humanised monoclonal antibody CCR5 antagonist – in treatment-naive HIV patients. The data were presented at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC.